Natural and synthetic furanocoumarins as treatment for vitiligo and psoriasis

Current Drug Therapy

Volumn 4, Issue 1, 2009, Pages 38-58

  Conforti, Filomena ^a   Marrelli, Mariangela ^a   Menichini, Federica ^a   Bonesi, Marco ^a   Statti, Giancarlo ^a   Provenzano, Eugenio ^b   Menichini, Francesco ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b Operative Unit of Dermatology   (Italy)

Author keywords

Natural and synthetic furanocoumarins; Phototherapy; Psoriasis; Vitiligo

Indexed keywords

1 THIOANGELICIN; 4,4',6 TRIMETHYLANGELICIN; ANGELICIN; BERGAPTEN; CNIDIADIN; FUROCOUMARIN DERIVATIVE; FUROQUINOLINONE DERIVATIVE; METHOXSALEN; PIRROLOQUINOLINONE DERIVATIVE; PSORALEN; PYRAZOLOCOUMARIN DERIVATIVE; THIOANGELICIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER RISK; CYTOTOXICITY; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG STRUCTURE; ERYTHEMA; FEVER; GENOTOXICITY; HUMAN; IMMUNOMODULATION; INFLAMMATION; LYMPHOMA; MELANOMA; MULTIPLE SCLEROSIS; MYCOSIS FUNGOIDES; NONHUMAN; PHOTOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; SKIN CANCER; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; VITILIGO;

EID: 65349096241     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488509787081886     Document Type: Review

References (138)

1. Menter A, Hamilton TK, Toth DP, et al. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, phase IIIb study. Int J Dermatol 2007; 46: 637-48.
2. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167-81.
3. Taieb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20: 27-35.
4. Nordlund JJ, Ortonne J-P, LePoole IC. Vitiligo vulgaris in the pigmentary system: physiology and pathophysiology. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne J-P, Eds. Oxford: Blackwell 2006; 551-98.
5. Harsoulis P, Kanakoudi-Tsakalidis F, Vyzantiadis A, Minas A, Cassimos C. Autoimmunity and vitiligo. Arch Dermatol 1978; 114: 1554.
6. Ortonne JP. What's new in the understanding of vitiligo. J Eur Acad Dermatol Venereol 1995; 5: S4-S5.
7. Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard RM, Nickoloff BJ, Das PK. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004; 9: 68-72.
8. Gauthier Y, Cario Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003; 16: 322-32.
9. Namazi MR. Prescribing cyclic antidepressants for vitiligo patients: which agents are superior, which are not? Psychother Psychosom 2003; 72: 361-2.
10. Martìnez D, Vermeulen M, von Euw E, et al. Extracellular acidosis triggers the maturation of human dendritic cells and the production of IL-12. J Immunol 2007; 179: 1950-59.
11. Huang CL, Nordlund JJ, Boissy R. Vitiligo: a manifestation of apoptosis? Am J Clin Dermatol 2002; 3: 301-08.
12. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000; 5: 415-8.
13. Dirckx J. Stedman's Concise Medical Dictionary. Philadelphia: Williams & Wilkins, 2001.
14. Ashcroft DM, Li Wan PA, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000; 25: 1-10.
15. Gottlieb AB. Psoriasis. Immunopathology and immunomodulation. Dermatol Clin 2001; 19: 649-57.
16. Krueger JG. The immunologic basis for the treatment of psorias is with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
17. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51.
18. Nickoloff BJ, Karabin GD, Barker JN, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factoralpha in psoriasis. Am J Pathol 1991; 138: 129-40.
19. Mease PJ. Cytokine blockers in psoriatic arthritis. Ann Rheum Dis 2001; 60: 37-40.
20. Mease PJ. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin Exp Rheumatol 2002; 20: S116-S121.
21. Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol 2000; 17: 174-8.
22. Morris A, Rogers M, Fischer G, Williams K. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol 2001; 18: 188-98.
23. Henseler T. The genetics of psoriasis. J Am Acad Dermatol 1997; 37: S1-S11.
24. Swanbeck G, Inerot A, Martinsson T, et al. Genetic counseling in psoriasis: empirical data on psoriasis among firstdegree relatives of 3095 psoriatic probands. Br J Dermatol 1997; 137: 939-42.
25. Ansel JC, Kaynard AH, Armstrong CA, et al. Skin-nervous system interactions. Dermatol Found 1995; 29: 1-12.
26. Diamond J, Holmes M, Coughin M. Endogenous NGF and nerve impulses regulate the collateral sprouting of sensory axons in the skin of the adult rat. J Neurosci 1992; 12: 1454-66.
27. Naukkarinen A, Nickoloff BJ, Farber EM. Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J Invest Dermatol 1989; 92: 126-9.
28. Al'Abadie MSK, Senior HJ, Bleehen SS, et al. Neurogenic changes in psoriasis. An immunohistochemical study. J Invest Dermatol 1992; 98: 535.
29. Rogers M. Childhood psoriasis. Curr Opin Pediatr 2002: 14: 404-9.
30. Howard R, Tsuchiya A. Adult skin disease in the pediatric patient. Dermatol Clin 1998: 16: 593-608.
31. Serup J, Niels R. Finsen: first Nobel laureate in medicine. Forum Nord Derm Ven 2003; 8: 98-100.
32. Scott BO. Clinical uses of ultraviolet radiation: therapeutic electricity and ultraviolet radiation. Licht S. Ed. (CT: Elizabeth Licht). 1967; 325-78.
33. Luger TA, Schwarz T. Effects of UV-light on cytokines and neuroendocrine hormones, In: Elmets C, Krutman J. (Eds.). Photoimmunology, Blackwell, London, 1995; 55-76.
34. Monfrecola G, de Paulis A, Prizio E, et al. In vitro effects of ultraviolet A on histamine release from human basophils. J Eur Acad Dermatol Venereol 2003; 17: 646-51.
35. Guhl S, Stefaniak R, Strathmann M, et al. Bivalent effect of UV light on human skin mast cells-low-level mediator release at baseline but potent suppression upon mast cell triggering. J Invest Dermatol 2005; 124: 453-6.
36. Walters IB, Ozawa M, Cardinale I, et al. Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: differential regulation of cytokines at the single-cell level. Arch Dermatol 2003; 139: 155-61.
37. Schwarz A, Beissert S, Grosse-Heitmeyer K, et al. Evidence for functional relevance of CTLA-4 in ultraviolet-radiation-induced tolerance. J Immunol 2000; 165: 1824-31.
38. Schwarz A, Maeda MK, Wild K, et al. Ultraviolet radiation-induced regulatory T cells not only inhibit the induction but can suppress the effector phase of contact hypersensitivity. J Immunol 2004; 172: 1036-43.
39. Weichenthal M, Schwarz T. Phototherapy: how does UV work? Photodermatol. Photoimmunol Photomed 2005; 21: 260-6.
40. Ozawa M, Ferenczi K, Kikuchi T, et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999; 189: 711-8.
41. Novak Z, Berces A, Ronto G, Pallinger E, Dobozy A, Kemeny L. Efficacy of different UV-emitting light sources in the induction of T-cell apoptosis. Photochem Photobiol 2004; 79: 434-9.
42. Morita A, Werfel T, Stege H, et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 1997; 186: 1763-8.
43. Matsunaga T, Hieda K, Nikaido O. Wavelength dependent formation of thymine dimers and (6-4) photoproducts in DNA by monochromatic ultraviolet light ranging from 150 to 365 nm. Photochem Photobiol 1991; 54: 403-10.
44. Aragane Y, Kulms D, Metze D, et al. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol 1998; 140: 171-182.
45. Kulms D, Zeise E, Poppelmann B, Schwarz T. DNA damage, death receptor activation and reactive oxygen species contribute to ultraviolet radiation-induced apoptosis in an essential and independent way. Oncogene 2002; 21; 5844-51.
46. Kalimo K, Koulu L, Jansen CT. Effect of a single UVB or PUVA exposure on immediate and delayed skin hypersensitivity reactions in humans. Correlation to erythemal response and Langerhans cell depletion, Arch Dermatol Res 1983; 275: 374-8.
47. Furio L, Berthier-Vergnes O, Ducarre B, Schmitt D, Peguet-Navarro J. UVA radiation impairs phenotypic and functional maturation of human dermal dendritic cells. J Invest Dermatol 2005; 125: 1032-8.
48. Hurks HM, Out-Luiting C, Vermeer BJ, Claas FH, Mommaas AM. The action spectra for UV-induced suppression of MLR and MECLR show that immunosuppression is mediated by DNA damage. Photochem Photobiol 1995; 62: 449-53.
49. British Photodermatology Group. British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994; 130: 246-55.
50. Pathak M, Fitzpatrick TB. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. J Photochem Photobiol B 1992; 14: 3-22.
51. Roelandts R. The history of photochemotherapy. Photodermatol Photoimmunol Photomed 1991; 8: 184-9.
52. Sakuntabhai A, Diffey BL, Farr PM. Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatment Br J Dermatol 1995; 133: 919-23.
53. Stevenson IH, Kenicer KJA, Johnson BE, Frain-Bell W. Plasma 8-methoxypsoralen concentrations in photochemotherapy of psoriasis. Br J Dermatol 1981; 104: 47-51.
54. Stern RS, Laird N. The carcinogenic risks of treatments for severe psoriasis. Cancer 1994; 73: 2759-64.
55. Stern RS, Nichols KP, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997; 336: 1041-5.
56. Parrish JA, Stern RS, Pathak MA, Fitzpatrick TB. Science of Photomedicine: NATO Conference Series, Regan JD, Parrish JA. Eds. New York: Plenum Press 1982; 595-624.
57. Gasparro FP. Extracorporeal Photochemotherapy: clinical aspects and the molecular basis for efficacy. Georgetown, TX: Landes Press 1994.
58. Wulff H, Rauer H, During T, et al. Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity. J Med Chem 1998; 41: 4542-9.
59. Bordin F, Dall'Acqua F, Guiotto A. Angelicins, angular analogs of psoralens: chemistry, photochemical, photobiological and photochemotherapeutic properties. Pharmacol Ther 1991; 52: 331-63.
60. Sayre RM, Dowdy JC. The increase in melanoma: are dietary furocoumarins responsible? Med Hypotheses 2008; 70: 855-9.
61. O'Kennedy R, Thornes RD. Coumarins-Biology, Applications and Mode of Action, John Wiley & Sons Ltda: Chichester, 1997.
62. Simões CMO, Schenkel EP, Gosmann G, Mello JCP, Mentz LA, Petrovick PR. Eds.; Farmacognosia: Da Planta ao Medicamento, 4th ed., Editora da UFSC: Florianópolis, SC; Editora da UFRS: Porto Alegre, RS, 2002.
63. Kimura Y, Ohminami H, Arichi H, et al. Effects of various coumarins from roots of Angelica dahurica on actions of adrenaline, ACTH and insulin in fat cells. Planta Med 1982; 45: 183-7.
64. Ishihara K, Fukutake M, Asano T, et al. Simultaneous determination of byak-angelicin and oxypeucedanin hydrate in rat plasma by column-switching high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001; 753: 309-14.
65. Xie Y, Chen Y, Lin M, Wen J, Fan G, Wu Y. High-performance liquid chromatographic method for the determination and pharmacokinetic study of oxypeucedanin hydrate and byak-angelicin after oral administration of Angelica dahurica extracts in mongrel dog plasma. J Pharm Biomed Anal 2007; 44: 166-72.
66. Sardari S, Amin GH, Sekhon A, Micetich RG, Daneshtalab M. Antifungal activity of Diplotaenia damavandica. Pharm Pharmacol Commun 2000; 6: 455-8.
67. Mar W, Je KH, Seo EK. Cytotoxic constituents of Psoralea corylifolia. Arch Pharm Res 2001; 24: 211-3.
68. Godoy MFP, Victor SR, Bellini AM, et al. Inhibition of the symbiotic fungus of leaf-cutting ants by coumarins. J Braz Chem Soc 2005; 16: 669-72.
69. Khatune NA, Islam ME, Haque ME, Khondkara P, Rahman MM. Antibacterial compounds from the seeds of Psoralea corylifolia. Fitoterapia 2004; 75: 228-230.
70. Lou FM, Yang J, Bai ZC, Wu BF. Studies on chemical constituents in rhizome of Elaeagnus bockii I. Zhongguo Zhong Yao Za Zhi 2006; 31: 988-9.
71. Rochette J, Craig JE, Thein SL. Fetal hemoglobin levels in adults. Blood Rev 1994; 8: 213-24.
72. Rodgers GP, Rachmilewitz EA. Novel treatment options in the severe γ-globin disorder. Br J Haematol 1995; 91: 263-8.
73. Lampronti I, Bianchi N, Borgatti M, Fibach E, Prus E, Gambari R. Accumulation of γ-globin mRNA in human erythroid cells treated with angelicin. Eur J Haematol 2003; 71: 189-95.
74. Backhouse CN, Delporte CL, Negrete RE, et al. Active constituents isolated from Psoralea glandulosa L. with antiinflammatory and antipyretic activities. J Ethnopharmacol 2001; 78: 27-31.
75. Okuyama T, Takata M, Takayasu J, et al. Anti-tumor-promotion by principles obtained from Angelica keiskei. Planta Med 1991; 57: 242-6.
76. Ashwood-Smith MJ, Poulton GA, Barker M, Mildenberger M. 5-Methoxypsoralen, an ingredient in several suntan preparations, has lethal, mutagenic and clastogenic properties. Nature 1980; 285: 407-9.
77. Schmitt IM, Chimenti S, Gasparro FP. Psoralen-protein photochemistry: a forgotten field. J Photochem Photobiol 1995; B27: 101-7.
78. Tassaneeyakul W, Guo L-Q, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000; 378: 356-63.
79. Baumgart A, Schmidt M, Schmitz H-J, Schrenk D. Natural furocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes. Biochem Pharmacol 2005; 69: 657-67.
80. Wang C-C, Lai J-E, Chen L-G, Yen K-Y, Yang L-L. Inducible nitric oxide synthase inhibitors of Chinese herbs. Part 2: naturally occurring furanocoumarins. Bioorg Med Chem 2000; 8: 2701-7.
81. Barthomeuf C, Grassi J, Demeule M, Fournier C, Boivin D, Béliveau R. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemother Pharmacol 2005; 56: 173-81.
82. Kofinas C, Chinou I, Loukis A, et al. Cytotoxic coumarins from the aerial parts of Tordylium apulum and their effects on a nonsmall-cell bronchial carcinoma line. Planta Med 1998; 64: 174-6.
83. Chang H, Okada Y, Okuyama T, Tu P. 1H and 13C NMR assignments for two new angular furanocoumarin glycosides from Peucedanum praeruptorum. Magn Reson Chem 2007; 45: 611-4.
84. Bordin F, Carlassare F, Baccichetti F, Guiotto A, Rodighiero P. 5-Methylangelicin: a new highly photosensitizing angular furocoumarin. Experientia 1979; 35: 1567-8.
85. Guiotto A, Rodighiero P, Pastorini G, et al. A new water soluble derivative of 4,5'-dimethylangelicin as a potential agent for photochemotherapy. Il Farmaco 1981; 36: 536-50.
86. Babudri N, Pani B, Venturini S, Monti-Bragadin C. Mutagenic activity of four furocoumarins: angelicin, 4,5'-dimethyl-angelicin, psoralen and 8-methyl-psoralen on V79 Chinese hamster cells. J Environ Pathol Toxicol Oncol 1986; 7: 123-9.
87. Cristofolini M, Recchia G, Boi S, et al. 6-Methylangelicins: new monofunctional photochemotherapeutic agents for psoriasis. Br J Dermatol 1990; 122: 513-24.
88. Baccichetti F, Bordin F, Carlassare F, et al. Furocoumarin for the photochemotherapy of psoriasis and related skin diseases. U.S. Patent 1982; 312: 883.
89. Baccichetti F, Bordin F, Monti-Bragadin, et al. A process of producing aikylangelicins and the product obtained therefrom. Republic of South Africa Patent 1984; 83: 7585.
90. Dall'Acqua F, Vedaldi D, Bordin F, et al. 4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis. J Med Chem 1983; 26: 870-6.
91. Guiotto A, Rodighiero P, Manzini P, et al. 6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis. J Med Chem 1984; 27: 959-67.
92. Vedaldi D, Dall'Acqua F, Caffieri S, et al. 4,4',5'-trimethyl-8-azapsoralen, a new photoactive and non skin-phototoxic bifunctional bioisoster of psoralen. Photochem Photobiol 1991; 53: 143-8.
93. Conconi MT, Montesi F, Parnigotto PP. Dietary self-selection can compensate an age-related decrease of rat liver 20 S proteasome activity observed with standard diet. J Gerontol A Biol Sci Med Sc 1998; 53: 173-9.
94. van Iperen HP, Brun BM, Caffieri S, Dall'Acqua F, Gasparro FP, Beijersbergen GMJ. The lack of efficacy of 4,6,6-trimethylangelicin to induce immune suppression in an animal model for photopheresis: a comparison with 8-MOP. Photochem Photobiol 1996; 63: 577-82.
95. Wolnicka-Glubisz A, Rajwa B, Dobrucki J, Skrzeczynska-Moncznik J, van Henegouwen GB, Sarna T. Phototoxicity, distribution and kinetics of association of UVA-activated chlorpromazine, 8-methoxypsoralen, and 4,6,4'-trimethylangelicin in Jurkat cells. J Photochem Photobiol B 2005; 78: 155-64.
96. Viola G, Fortunato E, Cecconet L, Del Giudice L, Dall'Acqua F, Basso G. Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544. Toxicol Appl Pharmacol 2008; 227: 84-96.
97. Dall'Acqua F, Marciani Magno S, Zambon F, Rodighiero G. Kinetic analysis of the photoreaction (365 nm) between psoralen and DNA. Photochem Photobiol 1979; 29: 489-95.
98. Stern RS, Lge R. Members of the photochemotherapy follow-up study. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120-4.
99. Vedaldi D, Dall'Acqua F, Baccichetti F, et al. Methylangelicins: structure activity studies on the role of methyl groups present in 3,4 and 4',5' photoreactive sites. Il Farmaco 1991; 46: 1381-406.
100. Baccichetti F, Bordin F, Simonato M, et al. Photobiological activity of certain new methylazapsoralens. Il Farmaco 1992; 47: 1529-41.
101. Jakobs AE, Christiaens LE, Renson MJ. Synthesis of monosulfur and monoselenium analogues of psoralen. Tetrahedron 1994; 50: 9315-24.
102. Rodighiero P, Guiotto A, Chilin A, et al. Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin disease. Synthesis, biological activity, mechanism of action and computeraided studies. J Med Chem 1996; 39: 1293-302.
103. Keil JM, Kampchen T, Seitz G. [4+2]-Cycloadditionen mit tetrabromcyclopropen: ein neuer syntheseweg zu polyfunktionalisierten indolen, benzofuranen und benzothiophenen. Tetrahedron Lett 1990; 31: 4581-4.
104. Jakobs AE, Christiaens L. A convenient synthesis of thiopyrano[2, 3-e]benzofuran: a new sulfur analogue of Angelicin. J Org Chem 1996; 61: 4842-4.
105. Vedaldi D, Dolmella A, Moro S, et al. 1-Thioangelicin: crystal structure, computer-aided studies and photobiological activity. Il Farmaco 2004; 59: 125-32.
106. Mosti L, Schenone P, Menozzi G, et al. Synthesis and photobiological activity of N,N-disubstituted 4-amino-3-chloro-2H-thieno[2,3-h]-1-benzopyran-2-ones, 7-thioisosteres of 4-amino-3-chloroangelicins. Il Farmaco 1984; 39: 81-94.
107. Mosti L, Lo Presti E, Menozzi G, et al. Synthesis of angelicin heteroanalogues: preliminary photobiological and pharmacological studies. Il Farmaco 1998; 53: 602-10.
108. Clarke DJ, Robinson RS. Synthesis of thio- and oxo-analogues of isopsoralen. Tetrahedron 2002; 58: 2831-7.
109. Miolo G, Caffieri S, Vedaldi D, et al. Photochemical and photobiological studies on methylthioangelicins. Il Farmaco 1999; 54: 134-44.
110. Vedaldi D, Caffieri S, Frank S, Dall'Acqua F, Jakobs A, Piette J. Sulfur and selenium analogues of psoralen as novel potential photochemotherapeutic agents. Il Farmaco 1995; 50: 527-36.
111. Rodighiero P, Pastorini G, Chilin A, Marotto A. Synthesis of methyl derivates of thienocoumarins and thiophyranocoumarins. J Heterocycl Chem 1998; 35: 847-52.
112. Bordin F, Marzano C, Baccichetti F, et al. Photobiological properties of 1'-thieno-4,6,4'-trimethylangelicin. Photochem Photobiol 1998; 68: 157-63.
113. Mosti L, Menozzi G, Schenone P, Carlassare F, Baccichetti F, Bordin F. Synthesis and photobiological activity of new N,N-disubstituted 4-amino-3-chloroangelicins. Il Farmaco 1988; 43: 775-92.
114. Fossa P, Mosti L, Menozzi G, Marzano C, Baccichetti F, Bordin F. Novel angular furo and thieno-quinolinones: synthesis and preliminary photobiological studies. Bioorg Med Chem 2002; 10: 743-51.
115. Bordin F, Marzano C, Carlassare F, et al. Photobiological properties of a new tetramethylfuroquinolinone. J Photochem Photobiol 1996; 34: 159-68.
116. Bordin F, Baccichetti F, Marzano C, et al. DNA damage induced by 4,6,8,9-tetramethyl-2H-furo[2,3-h]quinolin-2-one, a new furocoumarin analog: photochemical mechanisms. Photochem Photobiol 2000; 71: 254-62.
117. Marzano C, Baccichetti F, Carlassare F, Chilin A, Lora S, Bordin F. DNA damage induced by 4,6,8,9-tetramethyl-2H-furo[2,3-h]quinolin-2-one, a new furocoumarin analog: biological consequences. Photochem Photobiol 2000; 71: 263-72.
118. Marzano C, Caffieri S, Fossa P, Bordin F. Activity of 3-carbethoxyangelin photolysis product. J Photochem Photobiol B 1997; 38: 185-95.
119. Chilin A, Marzano C, Guiotto A. Baccichetti F, Carlassare F, Bordin F. Synthesis and biological evaluation of a new furo[2,3-h]quinolin-2(1H)-one. J Med Chem 2002; 45: 1146-9.
120. Chilin A, Marzano C, Baccichetti F, Simonato M, Guiotto A. 4-Hydroxymethyl- and 4-Methoxymethylfuro[2,3-h]quinolin-2(1H)-ones: synthesis and biological properties. Bioorg Med Chem 2003; 11: 1311-8.
121. Marzano C, Chilin A, Bordin F, Baccichetti F, Guiotto A. DNA damage and biological effects induced by photosensitization with new N1-unsubstituted furo[2,3-h]quinolin-2(1H)-ones. Bioorg Med Chem 2002; 10: 2835-44.
122. Marzano C, Chilin A, Baccichetti F, et al. 1,4,8-Trimethylfuro[2,3-H]quinolin-2(1H)-one, a new furocoumarin bioisoster. Eur J Med Chem 2004; 39: 411-9.
123. Barraja P, Diana P, Montalbano A, et al. Pyrrolo[2,3-h]quinolinones: a new ring system with potent photoantiproliferative activity. Bioorg Med Chem 2006; 14: 8712-28.
124. Dalla Via L, Gia O, Marciani-Magno S, Santana L, Teijeira M, Uriarte E. New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity. J Med Chem 1999; 42: 405-13.
125. Santana L, Uriarte E, Dalla Via L, Gia O. A new benzoangelicin with strong photobiological activity. Bioorg Med Chem Lett 2000; 10: 135-7.
126. González-Gómez JC, Santana L, Uriarte E. Synthesis and convenient functionalisation of pyridazinofurocoumarins: nitrogenated isosters of potent DNA inhibitors. Tetrahedron 2003; 59: 8171-6.
127. Oliveira AMAG, Oliveira-Campos AMF, Raposo MMM, et al. Psoralen analogues: synthesis, inhibitory activity of growth of human tumor cell lines and computational studies. Eur J Med Chem 2006; 41: 367-72.
128. Oliveira AMAG, Oliveira-Campos AMF, Rodrigues LM, et al. Synthesis and antitumor evaluation of benzopsoralen analogues. Chem Biodivers 2007; 4: 980-90.
129. Dall'Acqua F, Vedaldi D, Caffieri S, et al. New monofunctional reagents for DNA as possible agents for the photochemotherapy of psoriasis: derivatives of 4,5'-dimethylangelicin. J Med Chem 1981; 24: 178-84.
130. Traven VF, Kravtchenko DV, Chibisova TA. The first synthesis of furocoumarin dimmers. Mendeleev Commun 1997; 6: 249-50.
131. Traven VF, Tolmachev AY, Podhaluzina NY, Kanevskii DS, Solovieva NP. New ways of lactone ring shortening and cyclopropanation in coumarin derivatives. Hetrocycl Commun 1995; 5: 69-76.
132. Sakharuk II, Makarov IG, Traven VF. New heteroaromatic derivates of 6-amino-4-methylangelicin. Chem Heterocycl Comp 2001; 37: 453-8.
133. Tolmachev AY, Podkhalyuzina NY, Kuznetsova NA, Traven VF. New Synthesis of 8-Alkoxycarbonylangelicins. Russ J Org Chem 1999; 37: 1008-12.
134. Iester M, Fossa P, Menozzi G, et al. Synthesis and photobiological properties of 3-acylangelicins, 3-alkoxycarbonylangelicins and related derivatives. Farmaco 1995; 50: 669-78.
135. Marzano C, Caffieri S, Iester M, Bordin F, Averbeck D. Photobiological activity of 3-carbethoxyangelicin in Saccharomyces cerevisiae. Med Biol Environ 1994; 22: 15-9.
136. Marzano C, Severin E, Pani B, Guiotto A, Bordin F. DAN damage and cytotoxicity induced in mammalian cells by a tetramethylfuroquinolinone derivate. Environ Mol Mutag 1997; 29: 256-64.
137. Traven VF, Sakharuk II, Kravchenko DV, Ivashchenko AV. Dihydrofuro[2,3-H]coumarin-9-one-synthon in the synthesis of 6-substituted angelicins. Chem Heterocycl Comp 2001; 37: 283-93.
138. Martey CA, Vetrano AM, Whittemore MS, et al. Mechanism of growth inhibition in keratinocytes by mercurio-substituited 4'-5'-dihydropsoralens. Biochem Pharmacol 2002; 63: 2001-9.